This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): ribavirin

Description: Rebetol (Ribavirin) is approved for use in combination with pegylated interferon to treat hepatitis C (HCV) infection. Ribavirin belongs to a class of drugs called nucleoside analogs, which includes some anti-HIV drugs like zidovudine (AZT). Ribavirin works with pegylated interferon to help stop HCV from making new copies of itself, these drugs also help the immune system to kill HCV. Ribavirin used alone does not have any effect on HCV or HIV, but it helps pegylated interferon to be more effective.

Deal Structure: Merck & Co no longer reports revenues for Rebetol as of Q1 2012.

Schering-Plough has exclusive worldwide rights to market oral ribavirin for hepatitis C through a licensing agreement with ICN Pharmaceuticals.

In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.

Partners: Valeant Pharmaceuticals International, Inc.

Rebetol News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug